ibuprofen catalent 200 mg mīkstās kapsulas
catalent germany eberbach gmbh, germany - ibuprofēns - kapsula, mīkstā - 200 mg
ibuprofen catalent 400 mg mīkstās kapsulas
catalent germany eberbach gmbh, germany - ibuprofēns - kapsula, mīkstā - 400 mg
epromul 220 mg apvalkotās tabletes
pharmaswiss ceska republika s.r.o., czech republic - naproksēna nātrija sāls - apvalkotā tablete - 220 mg
etrixenal 250 mg tabletes
proenzi s.r.o., czech republic - naproksēns - tablete - 250 mg
rimal 5 mg/5 mg cietās kapsulas
medana pharma sa, poland - ramiprilum, amlodipinum - kapsula, cietā - 5 mg/5 mg
foradil aerolizer 12 mikrogrami inhalācijas pulveris cietās kapsulās
sandoz d.d., slovenia - formoterola fumarāta dihidrāts - inhalācijas pulveris, cietā kapsula - 12 µg
rimal 10 mg/5 mg cietās kapsulas
medana pharma sa, poland - ramiprilum, amlodipinum - kapsula, cietā - 10 mg/5 mg
rimal 10 mg/10 mg cietās kapsulas
medana pharma sa, poland - ramiprilum, amlodipinum - kapsula, cietā - 10 mg/10 mg
rimal 5 mg/10 mg cietās kapsulas
medana pharma sa, poland - ramiprilum, amlodipinum - kapsula, cietā - 5 mg/10 mg
blincyto
amgen europe b.v. - blinatumomab - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.